Skip to content

Author

P. Paliogiannis

We have 2 of 16 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Review Open access Aug 2026

Discrepancies in the Molecular Epidemiology of Druggable Genetic Alterations in Non-Small Cell Lung Cancer

Non-small cell lung cancer (NSCLC) represents most lung cancer diagnoses worldwide and remains a leading cause of cancer-related mortality. The advent of precision oncology has transformed the therapeutic landscape of NSCLC through the identification of druggable genetic alterations, enabling the use of targeted therap...

P. Paliogiannis, A. Zinellu, Giuseppe Palmieri et al. · 0 citations
Review Open access Aug 2026

Antibody–Drug Conjugates in Lung Cancer: Promise, Progress, and Persistent Challenges

The rationale for targeting established and emerging antigens in non-small cell and small cell lung cancer, including HER2, TROP2, c-MET, HER3, CEACAM5, DLL3, and other promising targets currently under clinical investigation are discussed.

P. Paliogiannis, G. Fara, A. Zinellu et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.